{"id":"NCT02034006","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.","officialTitle":"A 12-month, Open-label, Interventional, Multicentre Study to Investigate the Current Criteria Driving Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06-10","primaryCompletion":"2016-07-15","completion":"2016-07-15","firstPosted":"2014-01-13","resultsPosted":"2019-02-18","lastUpdate":"2019-02-18"},"enrollment":200,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Choroidal Neovascularization Secondary to Pathologic Myopia"],"interventions":[{"type":"DRUG","name":"Ranibizumab","otherNames":["RFB002"]}],"arms":[{"label":"Ranibizumab","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study was to investigate current criteria driving re-treatment in patients affected by Choroidal Neovascularization (CNV) secondary to Pathologic Myopia (PM) and experiencing a relapse of the disease after the first administration of ranibizumab.","primaryOutcome":{"measure":"Number of Patients Treated and Re-treated Based on Presence/Absence of Active Leakage","timeFrame":"Screening, Month 2, Month 6","effectByArm":[{"arm":"Ranibizumab: Treated Once","deltaMin":3,"sd":null},{"arm":"Ranibizumab: Re-treated Once","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":11},"locations":{"siteCount":31,"countries":["Italy"]},"refs":{"pmids":["30680452"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":200},"commonTop":["Choroidal neovascularisation (Study Eye)","Influenza","Conjunctival hyperaemia (Both Eyes)","Conjunctival haemorrhage (Study Eye)","Ocular hypertension (Both Eyes)"]}}